Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292771 | 0.99 | TPSAB1 (0.44) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL4600306 | 0.99 | TPSAB1 (0.44) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL4599808 | 0.99 | TPSAB1 (0.44) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL1637220 | 0.96 | KMT2A (0.47) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL4599868 | 0.96 | KMT2A (0.47) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL4600039 | 0.96 | KMT2A (0.47) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL4612508 | 0.92 | MALT1 (0.43) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL4717209 | 0.92 | MALT1 (0.43) | TPSAB1TPSD1TPSG1KMT2AMEN1 | |
| SCHEMBL9933024 | 0.91 | CXCR3 (0.45) | — | |
| SCHEMBL8893033 | 0.87 | CYP1A2 (0.37) | KMT2AGAAFOLH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | TPSAB1 4681/4885TPSD1 4609/4885TPSG1 4479/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | TPSAB1 3165/4885TPSD1 2971/4885TPSG1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.